|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3713 USD | +0.76% |
|
+3.43% | -72.29% |
| 06-08 | Soligenix Applies for Vaccine Development Funding for Bundibugyo Ebola Vaccine | CI |
| 05-28 | Soligenix - increases maximum offering under sales agreement by $2.96 million | RE |
Company Valuation: Soligenix, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 28.31 | 19.54 | 7.858 | 6.763 | 13.52 | 5.504 | - | - |
| Change | - | -30.98% | -59.78% | -13.94% | 99.84% | -59.27% | - | - |
| Enterprise Value (EV) | 28.31 | 19.54 | 7.858 | 6.763 | 13.52 | 5.504 | 5.504 | 5.504 |
| Change | - | -30.98% | -59.78% | -13.94% | 99.84% | -59.27% | 0% | 0% |
| P/E | -2.13x | -1.41x | -0.96x | -0.54x | -0.63x | -0.41x | -0.55x | -0.52x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.41x | 0x | 0x | 0x | 0x | 0x | -0.07x |
| Capitalization / Revenue | 35.4x | 21.7x | 9.36x | 56.7x | - | - | - | - |
| EV / Revenue | 0x | 0x | 0x | 0x | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.44x | -0.55x | -0.33x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -74.4 | -76.96 | -12.64 | -4.98 | -2.14 | -0.9 | -0.67 | -0.72 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 0.8 | 0.9 | 0.8394 | 0.1194 | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -13.14 | -14.24 | -7.698 | -9.44 | -11.85 | -12.5 | -9.95 | -16.6 |
| Net income 1 | -12.6 | -13.8 | -6.141 | -8.3 | -11.08 | -12.4 | -13.3 | -16.6 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 158.4719 | 108.4799 | 12.1152 | 2.6950 | 1.3400 | 0.3713 | 0.3713 | 0.3713 |
| Nbr of stocks (in thousands) | 179 | 180 | 649 | 2,509 | 10,086 | 14,824 | - | - |
| Announcement Date | 3/29/22 | 3/31/23 | 3/15/24 | 3/21/25 | 3/31/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.41x | - | - | - | 5.5M | |
| 33.56x | 8.38x | 25.87x | 0.05% | 57.28B | |
| 20.68x | 6.37x | 13.94x | 1.54% | 54.99B | |
| -41.86x | 13.29x | -39.17x | -.--% | 23.18B | |
| -17.88x | 4.15x | -7.26x | -.--% | 22.59B | |
| 25.74x | 5.04x | 13.35x | -.--% | 20.46B | |
| 24.54x | 4.77x | 15.5x | -.--% | 17.56B | |
| -787.21x | 37.41x | -4211.77x | -.--% | 15.67B | |
| 43.58x | 17.61x | 45.34x | 0.08% | 14.46B | |
| 17.42x | 5.04x | 11.77x | -.--% | 13.92B | |
| Average | -68.18x | 11.34x | -459.16x | 0.19% | 24.01B | |
| Weighted average by Cap. | -36.72x | 9.70x | -264.23x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SNGX Stock
- Valuation Soligenix, Inc.
Select your edition
All financial news and data tailored to specific country editions
